BRIEF published on 12/11/2025 at 23:05, 4 months 15 days ago Xenetic Biosciences Adjourns 2025 Annual Stockholders Meeting Xenetic Biosciences Stockholders Meeting Voting Instructions Quorum 2025 Adjournment
PRESS RELEASE published on 12/11/2025 at 23:00, 4 months 15 days ago Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting Xenetic Biosciences, Inc. adjourns 2025 Annual Meeting of Stockholders due to lack of quorum. Stockholders urged to vote before reconvened meeting on January 8, 2026 Xenetic Biosciences Stockholders Quorum Proxy Vote 2025 Annual Meeting
BRIEF published on 11/19/2025 at 14:50, 5 months 7 days ago Xenetic Biosciences Extends Collaboration with Scripps Research Cancer Treatment Biopharmaceutical DNase I CAR-T Therapy Scripps Research
PRESS RELEASE published on 11/19/2025 at 14:45, 5 months 7 days ago Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform Xenetic Biosciences extends collaboration with Scripps Research to advance DNase-based immuno-oncology treatment for cancers Xenetic Biosciences Immuno-oncology DNase I CAR-T Therapy Scripps Research
BRIEF published on 11/13/2025 at 14:50, 5 months 13 days ago Xenetic Biosciences Reports Q3 2025 Financial Results Financial Results Revenue Increase Clinical Trials Pancreatic Carcinoma DNase Technology
PRESS RELEASE published on 11/13/2025 at 14:45, 5 months 13 days ago Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results Xenetic Biosciences, Inc. reports Q3 2025 financial results, focuses on DNase-based technology for cancer treatment. Secured $3.9 million from offering, advancing collaborations Xenetic Biosciences Cancer Treatment Collaborations DNase Technology Q3 2025 Financial Results
BRIEF published on 10/10/2025 at 15:35, 6 months 16 days ago Xenetic Biosciences Announces $4.5 Million Stock Offering Xenetic Biosciences Biopharmaceutical Immuno-oncology Stock Offering Canaccord Genuity
PRESS RELEASE published on 10/10/2025 at 15:30, 6 months 16 days ago Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock Xenetic Biosciences, Inc. announces pricing of underwritten stock offering, aiming to raise $4.5 million for immuno-oncology technologies. Canaccord Genuity acts as bookrunner Xenetic Biosciences Stock Offering Immuno-oncology Technologies Canaccord Genuity S-3 Registration Statement
BRIEF published on 08/13/2025 at 14:05, 8 months 13 days ago Xenetic Biosciences Reports Q2 2025 Financial Results Financial Results Xenetic Biosciences Q2 2025 DNase I Development Partnership Expansions
PRESS RELEASE published on 08/13/2025 at 14:00, 8 months 13 days ago Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results Xenetic Biosciences, Inc. reports Q2 2025 results, expands partnership with The Scripps Research Institute for DNase I with CAR T-cell therapies and ends quarter with $4.8M cash Financial Results Xenetic Biosciences DNase I The Scripps Research Institute CAR T-cell Therapies
Published on 04/25/2026 at 03:10, 1 day 22 hours ago BEACN Announces Financial Results for Year Ended December 31, 2025
Published on 04/24/2026 at 22:05, 2 days 3 hours ago Critical Elements Mourns the Loss of Director Marc Simpson
Published on 04/24/2026 at 22:00, 2 days 3 hours ago Kidoz Inc. to Present 2025 Results and Highlight Platform Expansion and Business Momentum
Published on 04/24/2026 at 15:00, 2 days 10 hours ago Norsemont Reports Significant Copper, Lead & Zinc Values in Three Choquelimpie Drill Holes
Published on 04/24/2026 at 15:00, 2 days 10 hours ago First Canadian Graphite Appoints Scott Kelly As Chief Financial Officer
Published on 04/27/2026 at 01:05, 20 minutes ago GLN Connects to Vietnam's National QR Network, Enabling Nationwide QR Payments
Published on 04/26/2026 at 21:15, 4 hours 10 minutes ago Changan Group Unveils Updated "Vast Ocean Plan 2.0" and Highlight Next-Generation BlueCore Hybrid at Auto China 2026
Published on 04/26/2026 at 20:15, 5 hours 10 minutes ago Safety. For Family: TIGGO9 Completes Public Three-Vehicle Composite Crash Verification During the 2026 International Business Summit
Published on 04/26/2026 at 10:20, 15 hours 5 minutes ago EQS-Adhoc: Vitruvia Medical AG: Annual Results as of December 31, 2025
Published on 04/26/2026 at 09:05, 16 hours 20 minutes ago Natural Expressions Unveils Performance 7: The Era of "Drop-and-Mow" Wireless Robotic Mowing Arrives in Europe
Published on 04/24/2026 at 17:45, 2 days 7 hours ago Imerys-04-2026-information-share-capital-and-voting-rights-as-of-31-March-2026
Published on 04/24/2026 at 16:37, 2 days 8 hours ago Availability of the 2025 Universal Registration Document (URD)
Published on 04/23/2026 at 19:27, 3 days 5 hours ago Annual Shareholders' Meeting 2026 - Conditions of availability of the preparatory documents
Published on 04/23/2026 at 18:18, 3 days 7 hours ago Aéroports de Paris SA - Sale by Groupe ADP of securities representing 3.4% with option to sell an additional 3.9% of GAL's equity share capital to GMR Group
